The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

An Amgen executive refutes accusations that the company published misleading results of its mid-90s clinical trial testing an anemia drug.

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 

The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

Vesselon's microspheres optimize radiopharmaceuticals for targeted treatment, enhancing anti-tumor effects.

Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.

Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.

The watchdog website FDAAA TrialsTracker names and shames human studies that breach the FDA’s requirements for reporting results.